Myth: You need extensive thyroid testing before starting GLP-1 medications
The patients who keep weight off long-term combine medication with structured eating, resistance training, and protein adequacy
618 Until other ongoing trials such as ASTRO-APS (Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome) 624 clarify whether the increased risk of thrombosis with DOACs is a class effect versus an individual drug effect, we do not recommend the use of DOACs in general and, specifically, rivaroxaban for antiphospholipid syndrome
A patient who lost 55 pounds in eight months on semaglutide may have different tissue features than someone who lost the same amount with lifestyle changes over two to three years
In September 2024, the FDA sent a Warning Letter to the operators of a website advising the operators that misbranded and unapproved new drugs were being marketed for introduction into interstate commerce in violation of Sections 301(a), 301(d), 301(k), 503(b), and 505(a) of the FD&C Act
Competitive pricing and flexible treatment options
